Tenax Therapeutics is a biopharmaceutical company focused on the development and commercialization of innovative treatments for serious medical conditions, particularly in the area of cardiovascular diseases
The company is dedicated to advancing its proprietary therapies that aim to improve patient outcomes and enhance quality of life. By leveraging scientific expertise and engaging in strategic partnerships, Tenax Therapeutics seeks to bring groundbreaking solutions to the market, addressing unmet medical needs and providing hope for patients with chronic conditions.
Shares of Alcoa Corporation (NYSE: AA) rose sharply in today’s pre-market trading after the company reported better-than-expected sales for its first quarter.
Shares of Fangdd Network Group Ltd. (NASDAQ: DUO) rose sharply in today’s pre-market trading after the company announced its 2024 strategic layout with plans to enter the real estate stock asset services sector. Fangdd Network Group shares jumped 78.3% to $1.08 in pre-market trading
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 30 points on Thursday. The Dow traded down 0.01% to 38,675.29 while the NASDAQ rose 0.19% to 15,787.09. The S&P 500 also fell, dropping, 0.02% to 4,993.95.
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.29% to 38,565.98 while the NASDAQ rose 0.26% to 15,796.91. The S&P 500 also fell, dropping, 0.09% to 4,990.59.
U.S. stocks traded mixed this morning, following the release of jobless claims data on Thursday. Following the market opening Thursday, the Dow traded up 0.07% to 38,703.01 while the NASDAQ fell 0.07% to 15,746.25. The S&P 500 also fell, dropping, 0.06% to 4,991.87.
Shares of Fortinet, Inc. (NASDAQ: FTNT) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued guidance.
Tenax Therapeutics sees a surge in shares as US regulators allow its patent application for heart failure therapy, levosimendan, extending IP protection.
